A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice

NCT05069545 · clinicaltrials.gov ↗

COMPLETED

Status

411

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Insulin degludec
DRUG: Fast-acting insulin aspart

Sponsor

Novo Nordisk A/S